BridgeMD
Complement Inhibition: Attacking the Overshooting Inflammation @fter Subarachnoid Hemorrhage
EU CTIS ID: 2025-520540-15-00
What this study is testing
To study the safety and efficacy of C1-inhibitor Cinryze, an approved inhibitor of the complement system, compared to placebo in patients with SAH. By temporarily blocking the complement system we hypothesize limitation of delayed cerebral ischemia and a more favourable clinical outcome for SAH patients due to a decrease in the inflammatory response.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan
- Age of 18 years or above
- WFNS grade 1-5
You likely can't join if
- Subarachnoid hemorrhage deemed most likely of peri mesencephalic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
- Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
- Participation in another clinical therapeutic study
- Patients with definite infaust prognosis on arrival and/or expected death within 24 hours of admission
- Patients with a known hereditary complement deficiency (including hereditary angioedema)
- Patients with a history of sensibility to blood products or C1-inhibitor
See the full eligibility criteria
- Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan
- Age of 18 years or above
- WFNS grade 1-5
- Subarachnoid hemorrhage deemed most likely of peri mesencephalic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
- Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)
- Participation in another clinical therapeutic study
- Patients with definite infaust prognosis on arrival and/or expected death within 24 hours of admission
- Patients with a known hereditary complement deficiency (including hereditary angioedema)
- Patients with a history of sensibility to blood products or C1-inhibitor
- Patients with a know history of thrombosis (when known at time of inclusion)
- Pregnant women
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.